Sahil Kirpekar - 13 Mar 2024 Form 4 Insider Report for ATAI Life Sciences N.V. (ATAI)

Role
Chief Business Officer
Signature
/s/ Ryan Barrett , Attorney-in-fact
Issuer symbol
ATAI
Transactions as of
13 Mar 2024
Transactions value $
$0
Form type
4
Filing time
15 Mar 2024, 20:16:23 UTC
Previous filing
16 Mar 2023
Next filing
04 Apr 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ATAI Common Shares Options Exercise +100K 100K 14 Mar 2024 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ATAI Stock Option Award $0 +550K $0.00 550K 13 Mar 2024 Common Shares 550K $1.84 Direct F2
transaction ATAI Restricted Stock Units Options Exercise $0 -100K -50% $0.00 100K 14 Mar 2024 Common Shares 100K Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit represents a contingent right to receive one common share of the Issuer upon vesting and settlement. 50% of the restricted stock units will vest on the first anniversary of the grant date and 50% will vest on the second anniversary of the grant date.
F2 The stock option shall vest as to 25% of the underlying shares on January 1, 2025, and in 36 substantially equal monthly installments thereafter.